(MedPage Today) — At the American Society of Clinical Oncology (ASCO) meeting, studies focusing on antibody-drug conjugates (ADCs) across multiple breast cancer subtypes highlighted not only the expanding role of these therapies, but also the…
Source link : https://www.medpagetoday.com/meetingcoverage/ascofuturefocusmbrca/122079
Author :
Publish date : 2026-07-07 17:30:00
Copyright for syndicated content belongs to the linked Source.
